BACKGROUND: Moradabad district in Uttar Pradesh reported the highest number of paralytic polio cases in India during 2001-2007. We conducted a study in Moradabad in 2007 to assess seroprevalence against poliovirus types 1, 2, and 3 in children 6-12 and 36-59 months of age to guide future strategies to interrupt wild poliovirus transmission in high-risk areas. METHODS: Children attending 10 health facilities for minor illnesses who met criteria for study inclusion were eligible for enrollment. We recorded vaccination history, weight, and length and tested sera for neutralizing antibodies to poliovirus types 1, 2, and 3. RESULTS: Poliovirus type 1, 2, and 3 seroprevalences were 88% (95% confidence interval [CI], 84%-91%), 70% (95% CI, 66%-75%), and 75% (95% CI, 71%-79%), respectively, among 467 in the younger age group (n=467), compared with 100% (95% CI, 99%-100%), 97% (95% CI, 95%-98%), and 93% (91%-95%), respectively, among 447 children in the older age group (P<.001 for all serotypes). CONCLUSIONS: This seroprevalence study provided extremely useful information that was used by the program in India to guide immunization policies, such as optimizing the use of different OPV formulations in vaccination campaigns and strengthening routine immunization services. Similar surveys in populations at risk should be performed at regular intervals in countries where the risk of persistence or spread of indigenous or imported wild poliovirus is high.
BACKGROUND: Moradabad district in Uttar Pradesh reported the highest number of paralytic polio cases in India during 2001-2007. We conducted a study in Moradabad in 2007 to assess seroprevalence against poliovirus types 1, 2, and 3 in children 6-12 and 36-59 months of age to guide future strategies to interrupt wild poliovirus transmission in high-risk areas. METHODS: Children attending 10 health facilities for minor illnesses who met criteria for study inclusion were eligible for enrollment. We recorded vaccination history, weight, and length and tested sera for neutralizing antibodies to poliovirus types 1, 2, and 3. RESULTS: Poliovirus type 1, 2, and 3 seroprevalences were 88% (95% confidence interval [CI], 84%-91%), 70% (95% CI, 66%-75%), and 75% (95% CI, 71%-79%), respectively, among 467 in the younger age group (n=467), compared with 100% (95% CI, 99%-100%), 97% (95% CI, 95%-98%), and 93% (91%-95%), respectively, among 447 children in the older age group (P<.001 for all serotypes). CONCLUSIONS: This seroprevalence study provided extremely useful information that was used by the program in India to guide immunization policies, such as optimizing the use of different OPV formulations in vaccination campaigns and strengthening routine immunization services. Similar surveys in populations at risk should be performed at regular intervals in countries where the risk of persistence or spread of indigenous or imported wild poliovirus is high.
Authors: Imtiaz Hussain; Ondrej Mach; Atif Habib; Zaid Bhatti; Zamir Suhag; M Steven Oberste; William C Weldon; Roland W Sutter; Sajid B Soofi; Zulfiqar A Bhutta Journal: Pediatr Infect Dis J Date: 2017-09 Impact factor: 3.806
Authors: Oumar Guindo; Ondrej Mach; Seydou Doumbia; Daniel K Ekra; Abdoul H Beavogui; William C Weldon; M Steven Oberste; Roland W Sutter Journal: Vaccine Date: 2018-01-19 Impact factor: 4.169
Authors: Natalie A Molodecky; Isobel M Blake; Kathleen M O'Reilly; Mufti Zubair Wadood; Rana M Safdar; Amy Wesolowski; Caroline O Buckee; Ananda S Bandyopadhyay; Hiromasa Okayasu; Nicholas C Grassly Journal: PLoS Med Date: 2017-06-12 Impact factor: 11.069
Authors: Richter Razafindratsimandresy; Ondrej Mach; Jean-Michel Heraud; Barivola Bernardson; William C Weldon; M Steven Oberste; Roland W Sutter Journal: Heliyon Date: 2018-03-07
Authors: Michael Famulare; Christian Selinger; Kevin A McCarthy; Philip A Eckhoff; Guillaume Chabot-Couture Journal: PLoS Biol Date: 2018-04-27 Impact factor: 8.029
Authors: Sani Ousmane; Dan Dano Ibrahim; Ajay Goel; William S Hendley; Bernardo A Mainou; Tess Palmer; Aissata Diaha; Sharon A Greene; Ondrej Mach Journal: Open Forum Infect Dis Date: 2021-05-06 Impact factor: 3.835
Authors: Concepcion F Estivariz; Sarah D Bennett; Jacquelyn S Lickness; Leora R Feldstein; William C Weldon; Eva Leidman; Daniel C Ehlman; Muhammad F H Khan; Jucy M Adhikari; Mainul Hasan; Mallick M Billah; M Steven Oberste; A S M Alamgir; Meerjady D Flora Journal: PLoS Med Date: 2020-03-31 Impact factor: 11.069